Efficacy and Toxicity of Factor Xa Inhibitors

Maryna Bondarenko1, Christophe Curti2, Marc Montana3, Pascal Rathelot2, Patrice Vanelle2

1Assistance Publique - Hôpitaux de Marseille (AP-HM), Service de la pharmacie à usage intérieur de l’hôpital Nord, Marseille, France
2Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, Marseille, France Assistance Publique - Hôpitaux de Marseille (AP-HM), Service Central de la Qualité et de l’Information Pharmaceutiques, Marseille, France
3Aix-Marseille Université, CNRS, Institut de Chimie Radicalaire ICR, UMR 7273, Laboratoire de Pharmaco-Chimie Radicalaire, Marseille, France Assistance Publique - Hôpitaux de Marseille (AP-HM), Oncopharma, Marseille, France

Abstract


Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations. The new oral anticoagulants and parenteral otamixaban are under evaluation in clinical trials for VTE treatment, for VTE prevention in orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for cardiovascular event prevention in patients with acute coronary syndrome. These antithrombotic agents directly and selectively inhibit factor Xa, and do not require coagulation monitoring and dose adjustment. Several of these drugs have shown promising results and have the potential to either replace or act as alternatives to traditional anticoagulants (heparins, vitamin K antagonists).

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

J Pharm Pharm Sci, 16 (1): 74-88, 2013

Full Text:

PDF